Reimbursed Care Access in Bangladesh

Currently classified as a controlled substance under Bangladesh scheduling with no authorised medical use outside of approved clinical research. The Narcotics Control Act, 2018 and its schedules list psilocybin among controlled (Class‑B) substances, and enforcement is carried out by the Department of Narcotics Control. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. MDMA is treated as an illegal/illicit stimulant/entactogen in Bangladesh and subject to criminal enforcement by DNC and police. #

There is no public record of regulatory approval or local marketing of esketamine (Spravato) in Bangladesh, and it is not listed among marketed intranasal/esketamine products in local pharmaceutical registries or supplier listings; standard anaesthetic ketamine (racemate) is available commercially but esketamine (as a distinct registered antidepressant product) does not appear on local product lists or DNC communications. Licensed ketamine products (ketamine hydrochloride vials) are available from multiple Bangladeshi manufacturers for anaesthesia use, but esketamine’s novel psychiatric indication and branded intranasal formulation have no documented national approval or reimbursement pathway. # #

Ketamine (racemic ketamine hydrochloride) is a licensed and commonly used anaesthetic in Bangladesh, distributed by multiple manufacturers and available in hospital pharmacies for surgical and procedural use. Commercial product listings and national pharmacy sources show registered ketamine formulations (e.g., Ketalar and multiple local brands) marketed for anaesthesia and analgesia in clinical settings. #

Regulatory & enforcement context: despite its clinical availability, ketamine is explicitly controlled and its non‑medical possession, distribution and trafficking are criminal offences under the Narcotics Control Act, 2018; the DNC actively enforces those provisions (recent high‑profile seizures and trafficking arrests illustrate robust enforcement). This creates a dual picture: (1) legitimate, reimbursable/paid clinical use in hospitals and surgical centres for anaesthesia and related indications using licensed formulations, and (2) strict criminal control of diversion, illicit sales and cross‑border trafficking prosecuted under the Narcotics Control Act. # #

Insurance / reimbursement: Bangladesh does not operate a unified national pharmaceutical reimbursement scheme comparable to OECD public drug formularies; ketamine for anaesthesia is supplied and paid for via hospitals (public and private). Public hospitals procure anaesthetics through government procurement channels while private hospitals purchase from licensed distributors; there is no evidence of reimbursement for ketamine when used as a psychiatric intervention (e.g., for depression) and off‑label psychiatric use would be unfunded and institutionally determined. #

Medical indications & practice nuance: Ketamine’s authorised/standard indication in Bangladesh is for anaesthesia and procedural sedation (as reflected in product monographs and hospital use). There is growing global interest in ketamine for psychiatric indications, but in Bangladesh any such psychiatric/off‑label use would be institutionally governed, not broadly reimbursed, and subject to both medical regulatory oversight and narcotics control measures to prevent diversion. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Products or preparations containing DMT (including natural plant brews) are prohibited and enforcement is by the DNC under the Narcotics Control Act, 2018. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 5‑MeO‑DMT falls within the DNC’s controlled psychotropic/psychedelic categories and is subject to criminal penalties for non‑medical possession or trafficking. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no documented legal pathway or licensed clinical ibogaine programmes in Bangladesh. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Because ayahuasca preparations contain DMT (a controlled compound), importation, possession or ritual use would be illegal absent a specific government exemption (none publicly documented). # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline and peyote‑type materials are controlled and unlicensed in Bangladesh. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Novel phenethylamines (including 2C‑class compounds) are captured by Bangladesh’s scheduling and New Psychoactive Substances enforcement activities. # #